<DOC>
	<DOC>NCT00160680</DOC>
	<brief_summary>Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.</brief_summary>
	<brief_title>ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Clinical history of PER requiring treatment known at least since 2 years. Positive skin prick test (wheal &gt; 3 mm larger than the diluent control) or RAST (≥3.5 IU/ml) to HDM and Parietaria (less than 1 year). Minimum mean T4SS of 6 over baseline period. Subjects currently treated by specific parietaria pollen immunotherapy Subjects suffering from nonallergic asthma Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma) Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Persistent Allergic Rhinitis, HDM, Parietaria, sneezing, rhinorrhea, ocular pruritus, Rhinasthma, inflammatory cells, ICAM-1, ATAREAL, Xyzal, Levocetirizine</keyword>
</DOC>